Tagomics is at the forefront of disease diagnosis through its innovative multiomic platform, which integrates various biological data types, including genetic, epigenetic, and fragmentomic features. This proprietary technology is designed to identify disease-associated biomarkers, providing a comprehensive approach to understanding and diagnosing diseases. By leveraging advanced bioinformatics and machine learning techniques, Tagomics offers unique biological insights that significantly enhance genomics-based disease profiling. This transformative capability allows for a more nuanced understanding of diseases, potentially leading to improved diagnostic accuracy and patient outcomes.

The benefits of Tagomics' technology include high-throughput and cost-effective multiomic profiling, which is characterized by low sample input requirements and automation capabilities. The platform is sample-agnostic, ensuring reliability and reproducibility across various biological sources. Additionally, Tagomics has developed a seamless solution known as Interlace™, which streamlines the process of multiomic profiling, enabling the identification of disease-associated DNA biomarkers from diverse sample types. This innovative approach positions Tagomics as a leader in the field of epigenomic technologies, with significant implications for clinical applications and drug development.

United Kingdom

Tagomics is a privately held company founded in 2020, with 2-10 employees. It is working to transform disease diagnosis through genetic, epigenetic, and fragmentomic features to identify disease-associated biomarkers and provide insights for disease profiling.

Tagomics

Company Details